C4 Therapeutics Inc share price logo

C4 Therapeutics Inc

NASDAQ: CCCC

Small Cap

$3.11

-0.11

(-3.42%)

as on

C4 Therapeutics Inc Stock Performance

as on May 20, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $3.05
    $3.22
    downward going graph

    1.93%

    Downside

    3.54%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $1.21
    $3.95
    downward going graph

    61.09%

    Downside

    27.01%

    Upside

    downward going graph

C4 Therapeutics Inc share price movements today

Previous Close
$3.22
Open
$3.16
Volume
2.1M
Day's Low - High
$3.05 - $3.22
52 Week Low - High
$1.21 - $3.95

C4 Therapeutics Inc Historical Returns

1 Month Return
+ 21.92 %
3 Month Return
+ 67.92 %
1 Year Return
+ 131.17 %
3 Year Return
+ 8.87 %
5 Year Return
-89.63 %

C4 Therapeutics Inc Stock Fundamentals & Key Indicators

Check C4 Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$388.1M

EPS (TTM)

-1.03

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-102.5M

Revenue (TTM)

35.9M

Profit Margin

-292.08%

Return On Equity TTM

-44.44%

C4 Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of C4 Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$388.1M-89.63%NA-292.08%
BUY$31.8B357.47%NA0.00%
BUY$39.2B112.69%73.5512.55%
BUY$115.0B104.13%26.8935.51%
BUY$74.7B36.84%17.3929.65%

Stock Returns calculator for C4 Therapeutics Inc Stock including INR - Dollar returns

The C4 Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

C4 Therapeutics Inc investment value today

Current value as on today

₹2,28,300

Returns

₹1,28,300

(+128.3%)

Returns from C4 Therapeutics Inc Stock

₹1,01,948 (+101.95%)

Dollar Impact

₹26,352 (+26.35%)

Analyst Recommendation on C4 Therapeutics Inc Stock

Based on 15 analysts

BUY

73.33%

Buy

26.67%

Hold

0.00%

Sell

Based on 15 analysts, 73.33% of analysts recommend a 'BUY' rating for C4 Therapeutics Inc. Average target price of $11.57

C4 Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on C4 Therapeutics Inc.

What analysts predicted

73.12%UPSIDE

Target Price

$11.57

Current Price

$3.11

Analyzed by

15 Analysts

Target

$11.57

C4 Therapeutics Inc target price $11.57, a slight upside of 73.12% compared to current price of $3.11. According to 15 analysts rating.

Indian Investors' Interest in C4 Therapeutics Inc Stock

Search interest for C4 Therapeutics Inc Stock has increased by 26% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:26% versus previous 30 day period

C4 Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
3
3
12
15
5
7
6
11
11
6
Gross Profit
1
3
9
13
3
7
6
11
11
4
Operating Income
-37
-32
-21
-28
-37
-29
-28
-34
-23
-27
EBITDA
-32
-29
-15
-22
-32
-28
-27
-31
-22
-25
Interest Expense
2
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
-
Income Before Tax
-34
-28
-17
-24
-34
-26
-26
-32
-20
-25
Income Tax Expense
0
-2
-2
-2
0
-
-
-
0
-
Net Income
-34
-28
-17
-24
-34
-26
-26
-32
-20
-25
Net Profit Margin
-1065.75%
-933.23%
-147.56%
-160.57%
-667.82%
-363.66%
-402.60%
-286.43%
-185.97%
-408.47%

C4 Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
19
21
33
45
31
20
35
35
Gross Profit
-9
21
-45
45
31
13
35
27
Operating Income
-16
-35
-60
-82
-129
-139
-119
-104
EBITDA
-15
-31
-58
-80
-124
-122
-103
-102
Interest Expense
-
2
1
2
2
1
-
-
Depreciation
1
1
1
1
1
1
1
1
Income Before Tax
-15
-33
-65
-83
-128
-131
-105
-104
Income Tax Expense
0
0
0
2
-1
1
0
0
Net Income
-15
-34
-66
-83
-128
-132
-105
-104
Net Profit Margin
-81.14%
-159.48%
-199.83%
-183.23%
-412.19%
-638.34%
-295.96%
-292.08%

C4 Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-28
-17
-24
-34
-26
-26
-32
-20
-25
Operating Cash Flow
-18
-4
-24
-17
-33
-12
-31
-22
-29
Investing Cash Flow
-53
-11
0
13
29
38
4
-80
16
Financing Cash Flow
34
0
10
0
0
-
7
118
0
Change in Cash
-36
-16
-13
-4
-4
26
-19
15
-13

C4 Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-34
-66
-83
-128
-132
-105
-104
Operating Cash Flow
55
-67
-86
-105
-106
-65
-98
Investing Cash Flow
-1
-190
-189
58
158
-51
-8
Financing Cash Flow
0
348
171
1
45
45
126
Change in Cash
54
91
-104
-46
97
-71
19

Global Institutional Holdings in C4 Therapeutics Inc

Funds
Holdings
Vanguard Group Inc
3.98%
Wasatch Advisors LP
2.69%
BlackRock Inc
1.79%
TANG CAPITAL MANAGEMENT LLC
0.92%
Millennium Management LLC
1.08%

Insights on C4 Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, CCCC stock has moved up by 19.1%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 463.5% return, outperforming this stock by 454.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 259.9% return, outperforming this stock by 119.4%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -20.48M → -25.12M (in $), with an average decrease of 22.7% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 11.23M → 6.15M (in $), with an average decrease of 23.0% per quarter

About C4 Therapeutics Inc

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
OrganisationC4 Therapeutics Inc
Headquarters490 Arsenal Way, Watertown, MA, United States, 02472
IndustryBiotechnology
CEOMr. Andrew J. Hirsch M.B.A.
E-voting on sharesClick here to vote

Key Management of C4 Therapeutics Inc

Name

Title

Dr. Isabel Chiu Ph.D.

Senior Vice President of Strategic Alliances & Business Development

Ms. Kendra R. Adams

Chief Financial Officer and Head of Corporate Affairs & Treasurer

Ms. Paige Mahaney Ph.D.

Chief Scientific Officer

Ms. Kelly A. Schick

Chief People Officer

Dr. Nathanael S. Gray Ph.D.

Co-Founder & Member of Scientific Advisory Board

Mr. Mark Mossler

Chief Accounting Officer

Ms. Courtney Solberg

Senior Manager of Investor Relations

Mr. Andrew J. Hirsch M.B.A.

CEO, President & Director

Dr. Kenneth C. Anderson M.D., Ph.D.

Co-Founder, Independent Director & Member of Scientific Advisory Board

Dr. Leonard M. J. Reyno M.D.

Chief Medical Officer

FAQs

What is C4 Therapeutics Inc share price today?

C4 Therapeutics Inc share price today is $3.11 as on at the close of the market. C4 Therapeutics Inc share today touched a day high of $3.22 and a low of $3.05.

What is the 52 week high and 52 week low for C4 Therapeutics Inc share?

C4 Therapeutics Inc share touched a 52 week high of $3.95 on and a 52 week low of $1.21 on . C4 Therapeutics Inc stock price today i.e. is closed at $3.11,which is 21.27% down from its 52 week high and 157.02% up from its 52 week low.

What is C4 Therapeutics Inc's market capitalisation today?

C4 Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in C4 Therapeutics Inc Stock (CCCC) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for C4 Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in C4 Therapeutics Inc Shares that will get you 0.4823 shares as per C4 Therapeutics Inc share price of $3.11 per share as on May 20, 2026 at 8:46 am IST.

What is the minimum amount required to buy C4 Therapeutics Inc Stock (CCCC) from India?

Indian investors can start investing in C4 Therapeutics Inc (CCCC) shares with as little as ₹96.5325 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹965.33 in C4 Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on C4 Therapeutics Inc share’s latest price of $3.11 as on May 20, 2026 at 8:46 am IST, you will get 3.2154 shares of C4 Therapeutics Inc. Learn more about fractional shares .

What are the returns that C4 Therapeutics Inc has given to Indian investors in the last 5 years?

C4 Therapeutics Inc stock has given -89.63% share price returns and 31.59% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?